On December 7, 2023 MBrace Therapeutics, Inc. ("MBrace"), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, reported new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas (Press release, MBrace Therapeutics, DEC 7, 2023, View Source [SID1234638243]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data presented today further characterize the safety and activity of MBRC-101 and support its potential to effectively treat various solid tumors, including difficult-to-treat breast cancers," said Isan Chen, M.D., co-founder, president, and chief executive officer at MBrace. "We are advancing our clinical evaluation of MBRC-101 in breast cancer, as well as for patients with other EphA5-expressing solid tumor cancers for whom there is a significant need for targeted treatment options."

MBRC-101 is composed of a humanized anti-EphA5 IgG1 antibody conjugated to monomethyl auristatin E (MMAE). In the data presented today, robust and selective EphA5 expression was detected in greater than 80% of triple-negative breast cancer (TNBC) and greater than 80% of HR+ breast cancer tissue samples. EphA5 expression was not detected in adjacent, non-malignant breast tissue or normal breast.

Additionally, extensive in vitro testing showed that MBRC-101 binds to EphA5 exclusively, is rapidly internalized, and is cytotoxic to cells expressing EphA5. Dramatic preclinical efficacy was observed in vivo, with weekly administration of intravenous MBRC-101 showing dose-dependent, robust, and reproducible anti-tumor activity in patient-derived xenograft murine models of TNBC. In addition, in preclinical models, MBRC-101 was well tolerated at doses ranging from 10 mg/kg to 30 mg/kg. Toxicologic findings were attributed to the MMAE payload and not target-related. The highest non-severely toxic dose (HNSTD) was 10 mg/kg (HED = 3.2 mg/kg). At a dosage of 0.5 mg/kg, the safety margin was approximated at 15-fold based on projected human exposures.

The data presented are the results of research conducted both by MBrace, as well as in the laboratories of MBrace co-founders, Renata Pasqualini, Ph.D., Professor at Rutgers Cancer Institute of New Jersey and Chief of the Division of Cancer Biology at Rutgers New Jersey Medical School; and Wadih Arap, M.D., Ph.D., Professor and Chief of the Division of Hematology/Oncology and Director of the Rutgers Cancer Institute of New Jersey at University Hospital.

Details of the poster presentation are as follows:

Abstract Title: MBRC-101: a novel antibody-drug conjugate (ADC) targeting the membrane-associated tyrosine kinase receptor EphA5 in breast cancer

Presenter: Fernanda Staquicini, Ph.D., Director of Research & Development, MBrace Therapeutics

Presentation ID: P03-18-04

Spotlight Session: Poster Session 3

Session Date and Time: Thursday, December 7, 12:00 PM – 2:00 PM CST

Location: Henry B. Gonzalez Convention Center, San Antonio, Texas

Published Abstract Number: 1580268

The poster is also available on the MBrace Therapeutics website at www.mbractetrx.com.

About MBRC-101

MBRC-101 is an investigational antibody-drug conjugate (ADC) that uniquely targets the EphA5 receptor tyrosine kinase, which is present in multiple cancers including, but not limited to, breast, non-small cell lung (NSCLC), colorectal, gastric, and pancreatic cancers. MBRC-101 is currently being evaluated in the MBRC-101-001 Phase 1 clinical trial, a first-in-human, open-label, multicenter, dose escalation and dose expansion study enrolling patients with advanced metastatic solid tumors refractory to standard-of-care treatment. For more information about the MBRC-101-001 clinical trial and to review patient eligibility criteria visit clinicaltrials.gov (NCT06014658).

On December 7, 2023 IngenOx Therapeutics, an Oxford-based biopharmaceutical company, reported that its Chief Medical Officer, Prof. David Kerr had published a review on the use of diagnostic biomarkers to personalise adjuvant therapy for patients with colorectal carcinoma (Press release, IngenOx Therapeutics, DEC 7, 2023, View Source [SID1234638241]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The review, titled Personalizing adjuvant therapy for patients with colorectal cancer (View Source) is published in Nature Reviews – Clinical Oncology.

Currently, the standard adjuvant treatment for colorectal cancer (CRC) uses a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent, or in combination with oxaliplatin, spanning 3 to 6 months. The choice of therapy hinges on conventional histopathological staging procedures, which are considered blunt tools for patient stratification.

In contrast, high precision methods allow patients to be stratified into separate groups for different types of treatment. For example, CRC patients with low risk of disease recurrence and a high chance of cure by surgery, versus those with higher risk of cancer recurrence, who would derive greater benefits from chemotherapy.

To this end, in-depth genetic analyses were performed, leading to the discovery of germline determinants of toxicity from fluoropyrimidines. This allows for the identification of patients at high risk of life-threatening toxicity, enabling dose modulation to improve safety.

Further, the review described the application of artificial intelligence-driven models, trained from digital images of resected tissue, to help stratify cancer patients into distinct prognostic groups. The review also touches on liquid biopsy approaches involving measurements of circulating tumour DNA after surgery which are useful tools to identify patients at high and low risk of tumour recurrence.

The review concludes that the wider adoption of the new diagnostic technologies will better enable personalisation of adjuvant therapy for patients with CRC.

David Kerr, CMO of IngenOx, and Professor of Cancer Medicine at the University of Oxford commented:

"This review points the way forward, harnessing both tissue and blood-based assays to better enable selection of patients for adjuvant chemotherapy following apparently curative surgery – influencing treatment of approximately 1 million new patients per year. This review builds on my 30 year experience of leading the UK’s national adjuvant trials portfolio and associated insights into the biology and natural history of colorectal cancer – truly embracing personalised cancer therapy."

IngenOx Therapeutics is a bio-pharmaceutical company focused on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours. It is a spinout from the University of Oxford, and is located in the Oxford Science Park, UK. Its pipeline comprises early to late-stage products that work in different ways to activate the immune response against cold tumours, which are generally poorly recognised by the immune system. An exciting proprietary platform technology focusses on precision cancer vaccines that act by targeting the immune response to a novel source of cancer antigens.

On December 7, 2023 FORE Biotherapeutics reported that the Company will be presenting at the 2023 RBC Capital Markets Private Company Conference (Press release, Fore Biotherapeutics, DEC 7, 2023, View Source [SID1234638240]). The virtual presentation will take place on Thursday, December 14, 2023, from 8:00-8:30 a.m. ET. Shawn M. Leland, PharmD, RPh, Interim Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your RBC Capital Markets salesperson or Argot Partners to schedule one-on-one meetings with the management team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 7, 2023 FibroBiologics, Inc., a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, reported that it will hold an Investor Day on December 14, 2023, at 10 a.m. EST (Press release, FibroBiologics, DEC 7, 2023, View Source [SID1234638239]). A live webcast will be accessible here as well as on the FibroBiologics website in the News section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The session will be held in connection with FibroBiologics’ registration statement on Form S-1 (File No.: 333-275361) filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2023, relating to the proposed registration and public listing of the company’s common stock.

While FibroBiologics has filed a registration statement (including a preliminary prospectus, which can be found here) with the SEC for the direct listing to which this communication relates, any potential investor should read the preliminary prospectus in that registration statement and other documents FibroBiologics has filed with the SEC for more complete information about FibroBiologics prior to investing. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, a copy of the preliminary prospectus may be obtained from FibroBiologics through www.FibroBiologics.com. The registration statement relating to FibroBiologics’ common stock has not yet become effective and the common stock may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On December 7, 2023 Exelixis, Inc. (Nasdaq: EXEL) reported that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST (Press release, Exelixis, DEC 7, 2023, View Source [SID1234638237]). During the event, featured speakers will review the progress of the company’s growing research and development pipeline, highlight recent clinical updates and elaborate on the company’s continued efforts to serve more patients with cancer and generate sustainable, long-term value for shareholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be livestreamed and can be accessed via EXELRDDay.com. The registration access code is: EXELScience&Strategy. The webcast of the event will also be available at www.exelixis.com on the Event Calendar page under the Investors & News heading for one year.